Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials

Vandenberghe, R; Rinne, JO; Boada, M; Katayama, S; Scheltens, P; Vellas, B; Tuchman, M; ... Black, RS; + view all Vandenberghe, R; Rinne, JO; Boada, M; Katayama, S; Scheltens, P; Vellas, B; Tuchman, M; Gass, A; Fiebach, JB; Hill, D; Lobello, K; Li, D; McRae, T; Lucas, P; Evans, I; Booth, K; Luscan, G; Wyman, BT; Hua, L; Yang, L; Brashear, HR; Black, RS; - view fewer (2016) Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimer's Research & Therapy , 8 , Article 18. 10.1186/s13195-016-0189-7 . Green open access

http://bit.ly/2V2weMI